(0.05%) 5 472.16 points
(0.06%) 39 134 points
(0.37%) 17 784 points
(-0.01%) $80.82
(-3.66%) $2.66
(-0.76%) $2 313.20
(0.23%) $28.94
(3.64%) $1 022.30
(0.28%) $0.936
(0.70%) $10.68
(0.45%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally...
Stats | |
---|---|
今日成交量 | 908 991 |
平均成交量 | 2.83M |
市值 | 2.50B |
EPS | $0.0778 ( Q1 | 2024-05-09 ) |
下一个收益日期 | ( $0 ) 2024-08-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-538.50 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0130 (0.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-14 | Grossman Adam S | Sell | 460 000 | Common Stock |
2024-06-14 | Grossman Adam S | Sell | 10 000 | Common Stock |
2024-06-14 | Grossman Adam S | Sell | 100 000 | Common Stock |
2024-04-01 | Kestenberg-messina Kaitlin M. | Buy | 192 320 | Common Stock |
2024-04-01 | Kestenberg-messina Kaitlin M. | Buy | 300 328 | Stock Option (right to buy) |
INSIDER POWER |
---|
-21.38 |
Last 100 transactions |
Buy: 7 211 788 | Sell: 10 422 560 |
音量 相关性
ADMA Biologics Inc 相关性 - 货币/商品
ADMA Biologics Inc 财务报表
Annual | 2023 |
营收: | $258.21M |
毛利润: | $88.22M (34.16 %) |
EPS: | $-0.130 |
FY | 2023 |
营收: | $258.21M |
毛利润: | $88.22M (34.16 %) |
EPS: | $-0.130 |
FY | 2022 |
营收: | $154.08M |
毛利润: | $35.27M (22.89 %) |
EPS: | $-0.430 |
FY | 2021 |
营收: | $80.94M |
毛利润: | $1.17M (1.45 %) |
EPS: | $-0.832 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。